Hematopoietic Stem Cell TransplantationTransplantation, HomologousTransplantation ConditioningGraft vs Host DiseaseHematologic NeoplasmsMyeloablative AgonistsWhole-Body IrradiationBone Marrow TransplantationTransplantation, AutologousUnrelated DonorsGraft vs Tumor EffectHematopoiesisTissue DonorsGraft vs Leukemia EffectHematopoietic Stem CellsVidarabineHistocompatibility TestingGraft SurvivalTreatment OutcomeTransplantation ChimeraPeripheral Blood Stem Cell TransplantationLeukemia, Myeloid, AcuteChimerismRecurrenceRetrospective StudiesCord Blood Stem Cell TransplantationHistocompatibilitySiblingsBusulfanLeukemiaDonor SelectionStem Cell TransplantationSurvival AnalysisHLA AntigensMinor Histocompatibility AntigensMyelodysplastic SyndromesRemission InductionImmunosuppressive AgentsSurvival RateDisease-Free SurvivalHematologic DiseasesAllograftsPrecursor Cell Lymphoblastic Leukemia-LymphomaColony-Forming Units AssayTransplantation, IsogeneicAcute DiseaseBone Marrow CellsAntigens, CD34Graft RejectionCyclosporineLiver TransplantationHematopoietic Stem Cell MobilizationT-LymphocytesFollow-Up StudiesTime FactorsMycophenolic AcidLeukemia, Myelogenous, Chronic, BCR-ABL PositiveBone MarrowCombined Modality TherapyImmunosuppressionLymphoma, Non-HodgkinFetal BloodMice, Inbred C57BLRisk FactorsLiving DonorsTacrolimusLymphoproliferative DisordersCyclophosphamideGranulocyte Colony-Stimulating FactorLymphocyte DepletionChronic DiseaseKidney TransplantationSalvage TherapyLymphomaBlood Cell CountCell TransplantationTransplantation ImmunologyAge FactorsPrognosisCohort StudiesAntineoplastic AgentsCytomegalovirus InfectionsTransplantationFlow CytometryCD8-Positive T-LymphocytesCell LineageHeart TransplantationCell DifferentiationMice, SCIDIncidenceMultiple MyelomaDirected Tissue DonationCell SeparationSurvivorsLung TransplantationAntilymphocyte SerumProspective StudiesAnemia, AplasticMycosesHepatic Veno-Occlusive Disease